



InterMune UK & I Limited
Company Number 07700275

InterMune UK & I Limited
Report and Financial Statements
Year Ended 31 December 2021
Company Number 07700275



Contents	Pages
Strategic report	1
Report of the directors	2
Statement of directors' responsibilities in respect of the directors' report and the Financial Statements	3
Statement of Profit and Loss and Other Comprehensive Income	4
Balance sheet	5
Notes	6-8

Strategic report for year ended 31 December 2021

The directors present their strategic report together with the report of the directors and the audited financial statements for the year ended 31 December 2021.

Principal activities and business review

The principal activity of the company up to 28 February 2015 was a Limited Risk Distributor (LRD) for a branded pharmaceutical product- Esbriet® (indicated for treatment of IPF - Idiopathic Pulmonary Fibrosis) in the United Kingdom, Northern Ireland and the Republic of Ireland.

The company has not traded during the year.

Principal risks and uncertainties

As the company no longer trades- it is not exposed to any market or trading risk.

Financial risk management is performed by the ultimate parent company, Roche Holding Ltd, which also provides financial support to the company as required.

The directors do not envisage the company commencing a trade in the forthcoming period and hence these accounts are made up on a non-going concern basis.

On behalf of the board

Scott Davis

15. June 2022

Company Secretary
6 Falcon Way
Welwyn Garden City
Hertfordshire AL7 1TW

DocuSigned by:
Scott Davis
CDAA7D5DCD0F48E...

Report of the directors for year ended 31 December 2021

The directors present their report together with the audited financial statements for the year ended 31 December 2021.

Results and dividends

The company has not traded during the current or prior year and incurred no costs in either period. Accordingly no profit and loss account is included.

No dividends have been paid or are proposed for the year (2020: £nil)

Directors

R Erwin
Scott Davis
P Ward
Ms B Cuma

The Company made no political donations or incurred any political expenditure during the year.

Disclosure of information to the auditor

The directors who held office at the date of approval of this directors' report confirm that, so far as they are each aware, there is no relevant audit information of which the Company's auditor is unaware and each director has taken all the steps that he ought to have taken as a director to make himself aware of any relevant audit information and to establish that the Company's auditor is aware of that information.

Auditor

Pursuant to section 487 of the Companies Act 2006, the auditors will be deemed to be reappointed and KPMG LLP will therefore continue in office.

On behalf of the board

Scott Davis
Company Secretary
6 Falcon Way
Welwyn Garden City
Hertfordshire AL7 1TW

15. June 2022

DocuSigned by:
Scott Davis
CDAA7D5DCD0F4BE...

Statement of directors' responsibilities in respect of the Strategic Report, the Directors' Report and the Financial Statements

The directors are responsible for preparing the Strategic Report, the Directors' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law they have elected to prepare the financial statements in accordance with UK accounting standards and applicable law (UK Generally Accepted Accounting Practice), including FRS 101 Reduced Disclosure Framework.

Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- assess the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern; and
- use the going concern basis of accounting unless they either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error, and have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the company and to prevent and detect fraud and other irregularities.

The directors are responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in the UK governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Statement of profit and loss and other comprehensive income

During the current and prior year the company did not trade and received no income and incurred no expenditure. Consequently, during those years the company made neither a profit nor a loss.

Balance sheet at 31 December 2021

	Note	2021 £	2020 £
Current assets			
Debtors: amounts falling due within one year	3	3	3
		<u>3</u>	<u>3</u>
Current liabilities			
Creditors: amounts falling due within one year		-	-
		<u>-</u>	<u>-</u>
Net assets		<u>3</u>	<u>3</u>
		=====	=====
Share capital and reserves			
Called up share capital	4	3	3
		<u>3</u>	<u>3</u>
Shareholder's funds		<u>3</u>	<u>3</u>
		=====	=====

The notes on pages 6 to 8 form part of these financial statements.

For the year ended 31 December 2021 the company was entitled to exemption under section 480(2) of the Companies Act 2006. No members have required the company to obtain an audit of its accounts for the year in question in accordance with section 476(2). The directors acknowledge their responsibilities for complying with the 2006 Act requirements for accounting records and preparation of accounts.

These financial statements were approved by the board of directors on 15. June 2022 and were signed on its behalf by:

Richard Erwin

15. June 2022

Director
6 Falcon Way
Welwyn Garden City
Hertfordshire AL7 1TW

DocuSigned by:
Richard Erwin
A4CDE27DC2744FC...

Notes

1. Accounting policies

InterMune UK&I Limited (the "Company") is a Company incorporated and domiciled in the UK. The Company's registered office is Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire, AL7 1TW.

These financial statements were prepared in accordance with Financial Reporting Standard 101 Reduced Disclosure Framework ("FRS 101"). The amendments to FRS 101 (2018/19 Cycle) issued in July 2019 and effective immediately have been applied.

In preparing these financial statements, the Company applies the recognition, measurement and disclosure requirements of International Financial Reporting Standards as adopted by the EU ("Adopted IFRSs"), but makes amendments where necessary in order to comply with Companies Act 2006 and has set out below where advantage of the FRS 101 disclosure exemptions has been taken.

The Company's ultimate parent undertaking, Roche Holding AG, includes the Company in its consolidated financial statements. The consolidated financial statements of Roche Holding AG are prepared in accordance with International Financial Reporting Standards and are available to the public.

In these financial statements, the Company has applied the exemptions available under FRS 101 in respect of the following:

- A cash flow statement and related notes;
- Disclosures in respect of transactions with wholly owned subsidiaries; • Disclosures in respect of capital management; and
- The effects of new but not yet effective IFRSs.

The accounting policies set out below have been applied consistently to all periods presented in these financial statements.

Measurement convention

The financial statements are prepared on the historical cost basis.

Notes**1. Accounting policies****Going concern**

The principal activity of the company up to 28 February 2015 was a Limited Risk Distributor (LRD) for a branded pharmaceutical product- Esbriet® (indicated for treatment of IPF - Idiopathic Pulmonary Fibrosis) in the United Kingdom, Northern Ireland and the Republic of Ireland. After that date the company has not traded and as the directors do not intend to acquire a replacement trade, they have not prepared the financial statements on a going concern basis.

Foreign currency

Foreign currency transactions are translated into sterling at the rates ruling when they occurred. Foreign currency monetary assets and liabilities are translated at the rates ruling at the balance sheet date. Any differences are taken to the profit and loss account.

Trade and other debtors / creditors

Trade and other debtors are recognized initially at transaction price less attributable transaction costs. Trade and other creditors recognized initially at transaction price less attributable transaction costs. Subsequent to initial recognition they are measured at amortised cost using effective interest method, less any impairment losses in the case of trade debtors.

2. Expenses and auditor's remuneration

Included in profit are the following:

	2021	2020
Auditors remuneration:		
- fees receivable by the auditors for audit services in relation to the Company (these fees have been paid by a fellow group undertaking)	5000	5,000
	=====	=====

3. Debtors

	2021	2020
	£	£
Amounts owed by group companies	3	3
	<u>3</u>	<u>3</u>
	=====	=====

Notes *(continued)***4. Share capital**

	2021	2020
	£	£
Allotted, called up and fully paid		
3 ordinary shares of £1 each	3	3
	=====	=====

5. Ultimate parent company and parent company of the larger group

The Company is a subsidiary undertaking of Roche Holding AG which is the ultimate parent company incorporated in Switzerland. The ultimate controlling party is also Roche Holding AG whose address is Grenzacherstrasse 124, 4070 Basel, Switzerland. The entity in which the results of the Company are consolidated is that headed by Roche Holding AG, incorporated in Switzerland. No other group financial statements include the results of the Company. The consolidated financial statements of the Roche Group are available to the public and may be obtained from the Company Secretary, Roche Products Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW or on the internet at <http://www.roche.com>.

6. Related party transactions

No transactions were carried out by the Company with its managers and directors.